🔗 Share this article The Global Health Body Issues Alert Over Severe Scarcity of Weight-Loss Injections Less than one in 10 individuals eligible to benefit from obesity jabs such as Wegovy have access to them, caution the World Health Organization as it publishes its first guidance on the drugs. Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for increased and just availability to this class of drugs. According to forecasts, over two billion will be living with obesity by 2030 without intervention. "The latest guidance affirms that excess weight is a long-term condition that can be managed with thorough and ongoing support," stated its chief Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and distribution challenges are significant obstacles to widespread access to the injections that can help people shift significant body mass, notes the organization. Skinny Jab Scarcity Even in the present most optimistic case, the supply of GLP-1 therapies might only reach around 100 million people – under 10% of the global need, according to the WHO. The recommendation encourages countries and companies to expand availability, via measures like patent sharing. Exclusive production rights on a key compound – the core component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026. How Obesity Jabs Operate The injections replicate a body's own hormone to slow digestion, reduce hunger and increase satiety so individuals eat less. Individuals typically begin shedding pounds after several weeks of starting on the weekly injections. Studies suggests people may regain a significant portion after a year of halting the treatment, because their usual hunger return. To be overweight or obese increases your risk for experiencing health problems, including diabetes, heart disease, brain attack, and some malignancies. Obesity concerns individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.
Less than one in 10 individuals eligible to benefit from obesity jabs such as Wegovy have access to them, caution the World Health Organization as it publishes its first guidance on the drugs. Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for increased and just availability to this class of drugs. According to forecasts, over two billion will be living with obesity by 2030 without intervention. "The latest guidance affirms that excess weight is a long-term condition that can be managed with thorough and ongoing support," stated its chief Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and distribution challenges are significant obstacles to widespread access to the injections that can help people shift significant body mass, notes the organization. Skinny Jab Scarcity Even in the present most optimistic case, the supply of GLP-1 therapies might only reach around 100 million people – under 10% of the global need, according to the WHO. The recommendation encourages countries and companies to expand availability, via measures like patent sharing. Exclusive production rights on a key compound – the core component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026. How Obesity Jabs Operate The injections replicate a body's own hormone to slow digestion, reduce hunger and increase satiety so individuals eat less. Individuals typically begin shedding pounds after several weeks of starting on the weekly injections. Studies suggests people may regain a significant portion after a year of halting the treatment, because their usual hunger return. To be overweight or obese increases your risk for experiencing health problems, including diabetes, heart disease, brain attack, and some malignancies. Obesity concerns individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.